05 Jun Notification
Peania, March 14, 2019 – Lavipharm S.A., pursuant to article 17 of the European Parliament and Council Regulation 596/2014 (EU) and its Board of Directors meeting held on 11.03.2019, hereby notifies the investor community that it will participate to the share capital increase amounting to € 3.492.000 of its 100% subsidiary “LAVIPHARM ACTIVE SERVICES SA”. Participation will be made in kind, in particular Lavipharm S.A. will contribute to Lavipharm Active Services A.E. its total participation in “PHARMA PLUS SA”, another Lavipharm subsidiary. This participation has been evaluated by the independent audit firm PKF Euro-Auditing SA to the amount of € 3.492.000.
With the aforementioned participation in the share capital increase of Lavipharm Active Services S.A., Lavipharm S.A. retains its 100% participation in the company, while at the same time it continues to participate indirectly, through its 100% subsidiary Lavipharm Active Services S.A., in the share capital of Pharma PLUS SA.